NCT03983161 - A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions

Healthy VolunteersHepatic Impairment

Interventions

DRUG

Fedratinib

Trial Locations (3)

Orlando Clinical Research Center OCRC, Orlando

University Of Miami Miller School Of Medicine, Miami

Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville